Gilead dan­gles $105M in quick cash to sign Schol­ar Rock to a dis­cov­ery deal for its grow­ing NASH pipeline

At last count Gilead $GILD had 3 clin­i­cal stage pro­grams for NASH in the pipeline, topped by their Phase III work on selon­sert­ib.

But that’s not enough.

To­day the big biotech — which is get­ting a brain trans­plant in the ex­ec­u­tive suite as Roche’s Daniel O’Day heads for the helm — added a dis­cov­ery pro­gram with Schol­ar Rock $SRRK on a slate of TGFβ in­hibitors for fi­brot­ic dis­eases, beef­ing up a port­fo­lio of drugs that en­com­pass NASH and di­a­bet­ic kid­ney dis­ease.  

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.